Gara Jalqabaatti › Saree Oljoo › Virginia › Arlington
Qorannoo klinikaalii Saree Oljoo Arlington, VA keessatti
Qorannoo 47 Saree Oljoo f Arlington fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
The Vanguard Study: Testing a New Way to Screen for Cancer
Namoota walitti qabaa jiraHojjettoota fayyaa simatamoo
- Inova Schar Cancer Institute, Fairfax · Miili 11 fagaatti
- Inova Fair Oaks Hospital, Fairfax · Miili 11 fagaatti
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Virginia Cancer Specialists, PC, Fairfax · Miili 11 fagaatti
A Study of PHST001 in Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- NEXT Oncology - Virginia, Fairfax · Miili 11 fagaatti
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Namoota walitti qabaa jiraSadarkaa 1/2
- Virginia Cancer Specialists, Fairfax · Miili 11 fagaatti
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
Namoota walitti qabaa jiraSadarkaa 2
- Virginia Cancer Specialists, Fairfax · Miili 11 fagaatti
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Namoota walitti qabaa jiraSadarkaa 1/2
- Inova Schar Cancer Institute, Fairfax · Miili 11 fagaatti
- Virginia Cancer Specialists, PC, Fairfax · Miili 11 fagaatti
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
Namoota walitti qabaa jiraSadarkaa 2
- Inova Schar Cancer Institute, Fairfax · Miili 11 fagaatti
Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy
Namoota walitti qabaa jiraSadarkaa 3
- Inova Schar Cancer Institute, Fairfax · Miili 11 fagaatti
Study of AVZO-021 in Patients With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Avenzo Therapeutics Recruiting Site, Fairfax · Miili 11 fagaatti
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Namoota walitti qabaa jiraSadarkaa 3
- Inova Schar Cancer Institute ( Site 0025), Fairfax · Miili 11 fagaatti
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
Namoota walitti qabaa jiraSadarkaa 3
- Research Site, Fairfax · Miili 11 fagaatti
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
Namoota walitti qabaa jiraSadarkaa 2
- Virginia Cancer Specialists, Fairfax · Miili 11 fagaatti
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Namoota walitti qabaa jira
- Inova, Fairfax · Miili 11 fagaatti
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Namoota walitti qabaa jiraSadarkaa 3
- Virginia Cancer Specialists, Fairfax · Miili 11 fagaatti
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
Namoota walitti qabaa jiraSadarkaa 2
- Inova Schar Cancer Institute, Fairfax · Miili 11 fagaatti
A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast Cancer
Namoota walitti qabaa jiraSadarkaa 1
- Next Virginia, Fairfax · Miili 11 fagaatti
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Namoota walitti qabaa jiraSadarkaa 1/2
- NEXT Oncology, Fairfax · Miili 11 fagaatti
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Namoota walitti qabaa jiraSadarkaa 3
- Inova Schar Cancer Institute, Fairfax · Miili 11 fagaatti
- Virginia Cancer Specialists, Fairfax · Miili 11 fagaatti
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Virginia Cancer Specialists, Fairfax · Miili 11 fagaatti
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Namoota walitti qabaa jiraSadarkaa 1
- NEXT Oncology - Virginia Cancer Specialists, Fairfax · Miili 11 fagaatti
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- NEXT Oncology, Fairfax · Miili 11 fagaatti
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
Namoota walitti qabaa jiraSadarkaa 1/2
- Next Oncology, Fairfax · Miili 11 fagaatti
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Virginia Cancer Specialists-Fairfax, Fairfax · Miili 11 fagaatti
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- NEXT Virginia, Fairfax · Miili 11 fagaatti
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Namoota walitti qabaa jiraSadarkaa 3
- Kaiser Permanente Tysons Corner Medical Center, McLean · Miili 5 fagaatti
- Kaiser Permanente-Burke Medical Center, Burke · Miili 11 fagaatti
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- NEXT Virginia, Fairfax · Miili 11 fagaatti
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- NEXT Virginia, Fairfax · Miili 11 fagaatti
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Inova Schar Cancer Institute, Falls Church · Miili 4 fagaatti
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Namoota walitti qabaa jiraSadarkaa 3
- Inova Schar Cancer Institute, Fairfax · Miili 11 fagaatti
- Inova Fair Oaks Hospital, Fairfax · Miili 11 fagaatti
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Namoota walitti qabaa jiraSadarkaa 3
- Virginia Cancer Specialists, Fairfax · Miili 11 fagaatti
E-Mindfulness Approaches for Living After Breast Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Inova Fairfax Hospital, Falls Church · Miili 4 fagaatti
- Kaiser Permanente Tysons Corner Medical Center, McLean · Miili 5 fagaatti
- Inova Schar Cancer Institute, Fairfax · Miili 11 fagaatti
- fi 1 dabalataa
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Namoota walitti qabaa jiraSadarkaa 1/2
- USOR Virginia Cancer Specialists, Fairfax · Miili 11 fagaatti
Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- NEXT Virginia, Fairfax · Miili 11 fagaatti
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- USO-Virginia Cancer Specialists, PC, Fairfax · Miili 11 fagaatti
Pre-Operative Window of ET to Inform RT Decisions (POWER II)
Namoota walitti qabaa jiraSadarkaa 3
- INOVA Schar Cancer, Fairfax · Miili 11 fagaatti
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- NEXT Oncology Virginia, Fairfax · Miili 11 fagaatti
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- NEXT, Fairfax · Miili 11 fagaatti
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
Namoota walitti qabaa jiraSadarkaa 1/2
- Virginia Cancer Specialists, Fairfax · Miili 11 fagaatti
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
Namoota walitti qabaa jiraSadarkaa 1/2
- Inova Schar Cancer Institute ( Site 0051), Fairfax · Miili 11 fagaatti
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Namoota walitti qabaa jiraSadarkaa 3
- Virginia Cancer Specialists, PC, Reston · Miili 14 fagaatti
- Virginia Cancer Specialists, Manassas · Miili 22 fagaatti
A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer
Namoota walitti qabaa jiraSadarkaa 1
- Virginia Cancer Specialists, Fairfax · Miili 11 fagaatti
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- NEXT Oncology Virginia, Fairfax · Miili 11 fagaatti
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- NEXT Virginia, Fairfax · Miili 11 fagaatti
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Namoota walitti qabaa jiraSadarkaa 1/2
- Virginia Cancer Specialists, Fairfax · Miili 11 fagaatti
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- NEXT, Virginia, Fairfax · Miili 11 fagaatti
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Namoota walitti qabaa jiraSadarkaa 1
- Inova Schar Cancer Center, Fairfax · Miili 11 fagaatti
- NEXT Virginia, Fairfax · Miili 11 fagaatti
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer
Namoota walitti qabaa jiraSadarkaa 1
- Biotheryx Investigative Site, Fairfax · Miili 11 fagaatti
Qorannoo Saree Oljoo magaalota biroo keessatti
- New York City, NYQorannoo 136
- Houston, TXQorannoo 126
- Boston, MAQorannoo 112
- Nashville, TNQorannoo 81
- Los Angeles, CAQorannoo 73
- Edison, NJQorannoo 68
- St. Louis, MOQorannoo 64
- Queens, NYQorannoo 64
- Durham, NCQorannoo 64
- Chicago, ILQorannoo 59
- Philadelphia, PAQorannoo 56
- Dallas, TXQorannoo 55
Qorannoo biroo Arlington keessatti
- Kansara Qara'a Non-Small CellQorannoo 104
- Kansara MetastatikiiQorannoo 53
- Kansarii ColorectalQorannoo 52
- Saree (Gosoota Hunda)Qorannoo 48
- Kansarii OvariiQorannoo 46
- Dhibee QaraQorannoo 41
- Kansa EndometiriyaaliiQorannoo 39
- Kansarii PancreasQorannoo 33
- Kansa Selii Skwaamoo Mataa fi MormaQorannoo 26
- Kansarii Hafuu Seli XiqqaaQorannoo 23
- Kanisa HarkaaQorannoo 20
- Kansaar Onnee Triple-NegativeQorannoo 20
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.